TY - JOUR
T1 - Intraperitoneal infusion of interleukin-2 in patients with malignant ascites
T2 - Phenotypic and functional effects on tumor-associated lymphocytes
AU - Melioli, Giovanni
AU - Baldini, Editta
AU - De Maria, Andrea
AU - Moretta, Lorenzo
PY - 1988/1
Y1 - 1988/1
N2 - The aim of the present study was to evaluate the effects of intraperitoneal interleukin-2 (IL-2) infusion on tumor-associated lymphocytes (TAL) and peripheral blood lymphocytes (PBL) in patients with malignant ascites. Six patients were given IL-2 daily for 14 days by intraperitoneal infusion using a delivery system. TAL were isolated from the ascitic fluid before (day 0) and 7 and 14 days after the initiation of the treatment. Although no variations were observed in cytolytic activity and surface markers of PBL, TAL showed an important increase in the percentage of cells expressing IL-2 receptors of lymphokine-activated killer (LAK)-l antigen (i.e., a surface molecule expressed by human LAK cells and their precursors). Perhaps more importantly, a sharp increase of natural killer activity and the de novo generation of LAK activity were also observed.
AB - The aim of the present study was to evaluate the effects of intraperitoneal interleukin-2 (IL-2) infusion on tumor-associated lymphocytes (TAL) and peripheral blood lymphocytes (PBL) in patients with malignant ascites. Six patients were given IL-2 daily for 14 days by intraperitoneal infusion using a delivery system. TAL were isolated from the ascitic fluid before (day 0) and 7 and 14 days after the initiation of the treatment. Although no variations were observed in cytolytic activity and surface markers of PBL, TAL showed an important increase in the percentage of cells expressing IL-2 receptors of lymphokine-activated killer (LAK)-l antigen (i.e., a surface molecule expressed by human LAK cells and their precursors). Perhaps more importantly, a sharp increase of natural killer activity and the de novo generation of LAK activity were also observed.
KW - Cytotoxicity
KW - Interleukin-2
KW - Intraperitoneal infusion
KW - Lymphocyte surface antigens
KW - Lymphokine-activated killer cells
KW - Natural killer cells
KW - Tumor-associated lymphocytes
UR - http://www.scopus.com/inward/record.url?scp=0023941355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023941355&partnerID=8YFLogxK
U2 - 10.1007/BF02918820
DO - 10.1007/BF02918820
M3 - Article
C2 - 3259716
AN - SCOPUS:0023941355
VL - 18
SP - 61
EP - 66
JO - Ricerca in Clinica e in Laboratorio
JF - Ricerca in Clinica e in Laboratorio
SN - 0940-5437
IS - 1
ER -